Amneal Continues To See Value In Complexity

After A ‘Solid’ 2022, Amneal Wants To Deliver On Complex Generics And Biosimilars

With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.

Dollar sign in maze
Amneal sees greater value in more complex areas • Source: Shutterstock

Amneal has reported a “solid” set of results for 2022, driving sales up by 6% to $2.21bn as it continues to move into more complex generics and kicks off in earnest its ambitions in biosimilars.

Citing growth from new generics launches as well as the expansion of its AvKare business (Also see "Amneal Takes...

More from Earnings

More from Business